The most recent PTPN2 and PTP1B active-site inhibitor, ABBV-CLS-484 (AC484), is the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy [105]. This evidence concerns the gene PTPN2 and cancer.